Cristal Therapeutics further strengthens its Scientific Advisory Board with appointment of Dr. Paul Lammers

Cristal Therapeutics Further Strengthens its Scientific Advisory Board with Appointment of Dr Paul Lammers Maastricht, The Netherlands, August 9, 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced the appointment of Dr Paul Lammers to its Scientific […]

Read more

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform Round led by Aglaia BioMedical Ventures and DROIA Oncology Ventures Funding used: to execute clinical phase Ib and phase IIa trials with CriPec® docetaxel to further leverage the CriPec® platform for oligonucleotides programs from proof […]

Read more

Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform

Initial goal to determine treatment efficacy of iTeos’ immuno-oncology drug candidates Option for iTeos to license Cristal’s proprietary nanotechnology platform for development of up to three immuno-oncology therapeutic candidates Maastricht, The Netherlands and Gosselies, Belgium – December 7th, 2016 – Cristal Therapeutics, a Dutch privately-held life sciences company developing novel nanomedicines against cancer and other […]

Read more

Cristal Therapeutics announces appointment of Edwin Klumper as Chief Medical Officer

Maastricht, The Netherlands, April 28, 2016 – Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform, today announced the appointment of Edwin Klumper as Chief Medical Officer. He will be responsible for the clinical strategy and development of Cristal Therapeutics’ range of nanomedicines. […]

Read more

Cristal Therapeutics starts clinical phase I trial with nanomedicine CriPec® docetaxel in patients with solid tumours

Maastricht, The Netherlands, September 29, 2015 – Cristal Therapeutics, a privately-held life sciences company developing innovative drugs against cancer and other diseases, today announced the recent start of a clinical phase I trial with its lead candidate CriPec® docetaxel in patients with solid tumours. For this trial, patients are being recruited in two clinical centres […]

Read more

Cristal Therapeutics Announces Collaboration With PX Biosolutions to Develop CriVac® Based vaccines

Maastricht, The Netherlands, July 14, 2015 – Cristal Therapeutics, a privately-held life sciences company developing innovative products against cancer and other diseases, by using its patented nanotechnology platforms, today announced the start of a collaboration with PX Biosolutions (Melbourne, Australia). The joint research and development is focussed on the application of Cristal Therapeutics’ vaccine technology […]

Read more

Cristal Therapeutics’ proprietary CriPec® nanomedicine platform and promising preclinical data highlighted in three recent publications

Maastricht, The Netherlands, 22 June 2015 – Cristal Therapeutics, a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases by using its proprietary CriPec® platform, today announced the publication of three articles on CriPec®-based nanomedicines in Nano Today, Journal of Controlled Release and Biomaterials. The publications are co-authored by Dr. Cristianne Rijcken, founder […]

Read more

Cristal Therapeutics announces formation of Scientific Advisory Board

Maastricht, The Netherlands, 22 May 2014 – Cristal Therapeutics, today announced the appointments of Prof. Dr. Rob Liskamp, Prof. Dr. Twan Lammers, Prof. Dr. Alberto Gabizon, Dr. Maninder Hora and Dr. William Zamboni to its new Scientific Advisory Board. Cristal Therapeutics is a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases, such […]

Read more

Cristal Therapeutics announces appointment of Jeroen Tonnaer as Chief Business Officer

Maastricht, The Netherlands, 21 April 2015 – Cristal Therapeutics, a privately-held life sciences company developing novel nanotherapeutics against cancer and other diseases, by using its patented CriPec® platform announced today the appointment of Jeroen Tonnaer as new Chief Business Officer responsible for Cristal Therapeutics’ business development, partnering and licensing activities. Jeroen obtained an MSc in […]

Read more

€6 million in new capital and new CEO

Maastricht, The Netherlands, December 15, 2014 – Biopharmaceutical company Cristal Therapeutics has completed a new financing round of over €6 million which includes investments from new and existing investors and a national innovation fund. Venture capital investor Chemelot Ventures joins as a new shareholder and existing investors Thuja Capital, BioGeneration Ventures, Nedermaas, Utrecht University Holding […]

Read more